

Chanida Vinayanuwattikun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8915269/publications.pdf>

Version: 2024-02-01

26
papers

213
citations

1039406

9
h-index

1058022

14
g-index

29
all docs

29
docs citations

29
times ranked

345
citing authors

#	ARTICLE	IF	CITATIONS
1	Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer. <i>Scientific Reports</i> , 2022, 12, 2167.	1.6	18
2	An open-label, randomized, controlled trial to evaluate the efficacy of antihistamine premedication and infusion prolongation in prevention of hypersensitivity reaction to oxaliplatin.. <i>Journal of Clinical Oncology</i> , 2022, 40, 12099-12099.	0.8	0
3	Development of a human antibody fragment directed against the alpha folate receptor as a promising molecule for targeted application. <i>Drug Delivery</i> , 2021, 28, 1443-1454.	2.5	3
4	Vimentin expression status is a potential biomarker for brain metastasis development in EGFR-mutant NSCLC patients. <i>Translational Lung Cancer Research</i> , 2021, 10, 790-801.	1.3	5
5	Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 572740.	1.3	4
6	Tubulin acetylation enhances lung cancer resistance to paclitaxel-induced cell death through Mcl-1 stabilization. <i>Cell Death Discovery</i> , 2021, 7, 67.	2.0	17
7	Artocarpin Targets Focal Adhesion Kinase-Dependent Epithelial to Mesenchymal Transition and Suppresses Migratory-Associated Integrins in Lung Cancer Cells. <i>Pharmaceutics</i> , 2021, 13, 554.	2.0	12
8	Bibenzyl analogue DS-1 inhibits MDM2-mediated p53 degradation and sensitizes apoptosis in lung cancer cells. <i>Phytomedicine</i> , 2021, 85, 153534.	2.3	8
9	The equivalency study of novel current standard 3-drugs combination regimen (ondansetron,) Tj ETQq1 1 0.784314 rgBT /Overlock 100T induce nausea and vomiting treatment, double blind placebo control trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12100-12100.	0.8	0
10	Whole-exome sequencing in advanced-stage sensitizing EGFR mutation non-small cell lung cancer: Explore resistance biomarkers to EGFR TKI treatment.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9039-9039.	0.8	0
11	Pongol Methyl Ether Inhibits Akt and Suppresses Cancer Stem Cell Phenotypes in Lung Cancer Cells. <i>Pharmaceutics</i> , 2021, 14, 1085.	1.7	3
12	GRP78/BiP determines senescence evasion cell fate after cisplatin-based chemotherapy. <i>Scientific Reports</i> , 2021, 11, 22448.	1.6	4
13	Caffeine Induces G0/G1 Cell Cycle Arrest and Inhibits Migration through Integrin $\beta 1$, $\beta 3$, and FAK/Akt/c-Myc Signaling Pathway. <i>Molecules</i> , 2021, 26, 7659.	1.7	8
14	Paradoxical prognostic phenomenon of plasma T-cell-derived circulating DNA level in advanced non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 1117-1125.	1.2	0
15	A novel TRPM7/O-GlcNAc axis mediates tumour cell motility and metastasis by stabilising c-Myc and caveolin-1 in lung carcinoma. <i>British Journal of Cancer</i> , 2020, 123, 1289-1301.	2.9	20
16	Structure-Activity Relationships and Molecular Docking Analysis of Mcl-1 Targeting Renieramycin T Analogues in Patient-derived Lung Cancer Cells. <i>Cancers</i> , 2020, 12, 875.	1.7	13
17	Low prevalence of p16-positive HPV-related head-neck cancers in Thailand: tertiary referral center experience. <i>BMC Cancer</i> , 2019, 19, 1050.	1.1	25
18	Feasibility Technique of Low-passage In Vitro Drug Sensitivity Testing of Malignant Pleural Effusion from Advanced-stage Non-small Cell Lung Cancer for Prediction of Clinical Outcome. <i>Anticancer Research</i> , 2019, 39, 6981-6988.	0.5	7

#	ARTICLE	IF	CITATIONS
19	A phase 2 study of s-1 plus leucovorin in patients with untreated advanced cholangiocarcinoma (CCA).. Journal of Clinical Oncology, 2018, 36, 467-467.	0.8	0
20	Efficacy and safety of additional olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting: A randomized, double-blind, placebo-controlled, crossover study.. Journal of Clinical Oncology, 2018, 36, 10019-10019.	0.8	0
21	Comparing programmed death ligand-1 expression on tumor cells before and after acquiring resistance to tyrosine kinase inhibitor in EGFR harbouring non-small cell lung cancer.. Journal of Clinical Oncology, 2017, 35, 11617-11617.	0.8	0
22	SHP-1 promoter 2 methylation in cerebrospinal fluid for diagnosis of leptomeningeal epithelial-derived malignancy (carcinomatous meningitis). Journal of Neuro-Oncology, 2016, 129, 395-403.	1.4	3
23	The role of SHP-1 promoter 2 hypermethylation detection of lymph node micrometastasis in resectable stage I non-small cell lung cancer as a prognostic marker of disease recurrence. International Journal of Clinical Oncology, 2014, 19, 586-592.	1.0	9
24	Prevalence of KRAS gene mutation in ampullary cancer in Thai patients.. Journal of Clinical Oncology, 2014, 32, e15175-e15175.	0.8	2
25	The impact of non-tumor-derived circulating nucleic acids implicates the prognosis of non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2013, 139, 67-76.	1.2	19
26	Epithelial-Specific Methylation Marker: A Potential Plasma Biomarker in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1818-1825.	0.5	28